Minjiang C. Chen

Peking Union Medical College Hospital, Peking Union Medical College
Beijing, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 111 publications

Delayed Occurrence of Lung Cancer Leptomeningeal Metastasis and Era-Associated Post-LM Survival: A 14-Year Single-Center Cohort Study.

Delayed Occurrence of Lung Cancer Leptomeningeal Metastasis and Era-Associated Post-LM Survival: A 14-Year Single-Center Cohort Study.

Journal: Thoracic cancer
Published: July 19, 2026

Decision-Support Framework for Nutritional Risk in Small Cell Lung Cancer: A Time-Series Model Using Imputation Strategies for Incomplete Clinical Data.

Decision-Support Framework for Nutritional Risk in Small Cell Lung Cancer: A Time-Series Model Using Imputation Strategies for Incomplete Clinical Data.

Journal: Thoracic cancer
Published: June 12, 2026

Sensitivity of different epidermal growth factor receptor (EGFR) exon 19 deletion subtypes to first-line osimertinib in Chinese non-small cell lung cancer patients.

Sensitivity of different epidermal growth factor receptor (EGFR) exon 19 deletion subtypes to first-line osimertinib in Chinese non-small cell lung cancer patients.

Journal: BMC cancer
Published: November 13, 2025

Divergent Tumor Immune Microenvironment and Response to Neoadjuvant Chemoimmunotherapy in Resectable Non-Small Cell Lung Cancer: A Single-Arm Phase II Trial.

Divergent Tumor Immune Microenvironment and Response to Neoadjuvant Chemoimmunotherapy in Resectable Non-Small Cell Lung Cancer: A Single-Arm Phase II Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 05, 2025

Alectinib versus crizotinib as the first-line treatment in patients with advanced ALK-positive non-small cell lung cancer: a Chinese real-world cohort study.

Alectinib versus crizotinib as the first-line treatment in patients with advanced ALK-positive non-small cell lung cancer: a Chinese real-world cohort study.

Journal: Translational lung cancer research
Published: September 30, 2025

Clinical outcomes and predictive factors of immunotherapy efficacy in non-small-cell lung cancer brain metastases: a comparative study.

Clinical outcomes and predictive factors of immunotherapy efficacy in non-small-cell lung cancer brain metastases: a comparative study.

Journal: BMC cancer
Published: September 22, 2025

Lung Adenocarcinoma with EGFR Exon 20 H773_V774delinsLM Mutation 
Sensitive to Furmonertinib: A Case Report

Lung Adenocarcinoma with EGFR Exon 20 H773_V774delinsLM Mutation 
Sensitive to Furmonertinib: A Case Report

Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer
Published: July 10, 2025

Subcutaneously Administered Tislelizumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Pharmacokinetics and Safety Results from the BGB-A317-103 Phase I Study.

Subcutaneously Administered Tislelizumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Pharmacokinetics and Safety Results from the BGB-A317-103 Phase I Study.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 09, 2025

The Clinical Characteristics, Treatment, and Prognosis of Lung Cancer in Young Patients in the New Era of Cancer Treatment: A Retrospective and Comprehensive Analysis.

The Clinical Characteristics, Treatment, and Prognosis of Lung Cancer in Young Patients in the New Era of Cancer Treatment: A Retrospective and Comprehensive Analysis.

Journal: Current oncology (Toronto, Ont.)
Published: July 07, 2025

Case Report: Histological Transformation to Atypical Carcinoid in RET Fusion-positive NSCLC Following Immune Therapy Resistance

Case Report: Histological Transformation to Atypical Carcinoid in RET Fusion-positive NSCLC Following Immune Therapy Resistance

Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer
Published: June 12, 2025

Efficacy and safety of sunvozertinib monotherapy as first-line treatment in NSCLC patients with EGFR exon 20 insertion mutations: A phase 2, single-center trial.

Efficacy and safety of sunvozertinib monotherapy as first-line treatment in NSCLC patients with EGFR exon 20 insertion mutations: A phase 2, single-center trial.

Journal: Cancer letters
Published: April 17, 2025

Vitamin D and Immune Checkpoint Inhibitors in Lung Cancer: A Synergistic Approach to Enhancing Treatment Efficacy.

Vitamin D and Immune Checkpoint Inhibitors in Lung Cancer: A Synergistic Approach to Enhancing Treatment Efficacy.

Journal: International journal of molecular sciences
Published: March 15, 2025
Showing 1-12 of 111

Last Updated: 09/26/2026